WO2002047670A1 - Traitement du dysfonctionnement sexuel male - Google Patents

Traitement du dysfonctionnement sexuel male Download PDF

Info

Publication number
WO2002047670A1
WO2002047670A1 PCT/IB2001/002399 IB0102399W WO0247670A1 WO 2002047670 A1 WO2002047670 A1 WO 2002047670A1 IB 0102399 W IB0102399 W IB 0102399W WO 0247670 A1 WO0247670 A1 WO 0247670A1
Authority
WO
WIPO (PCT)
Prior art keywords
npy
agent
med
inhibitor
npyi
Prior art date
Application number
PCT/IB2001/002399
Other languages
English (en)
Inventor
Alasdair Mark Naylor
Pieter Hadewijn Van Der Graaf
Christopher Peter Wayman
Original Assignee
Pfizer Limited
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0030647A external-priority patent/GB0030647D0/en
Priority claimed from GB0108730A external-priority patent/GB0108730D0/en
Priority claimed from GB0109910A external-priority patent/GB0109910D0/en
Priority claimed from GB0111037A external-priority patent/GB0111037D0/en
Priority claimed from US09/895,367 external-priority patent/US20020028799A1/en
Priority claimed from US09/905,846 external-priority patent/US6878529B2/en
Priority claimed from GB0120679A external-priority patent/GB0120679D0/en
Priority to IL15577501A priority Critical patent/IL155775A0/xx
Priority to JP2002549244A priority patent/JP2004522720A/ja
Priority to AU2002220977A priority patent/AU2002220977A1/en
Priority to CA002431747A priority patent/CA2431747A1/fr
Priority to HU0400528A priority patent/HUP0400528A2/hu
Application filed by Pfizer Limited, Pfizer Inc. filed Critical Pfizer Limited
Priority to NZ526925A priority patent/NZ526925A/en
Priority to KR10-2003-7007946A priority patent/KR20030061441A/ko
Priority to EP01270206A priority patent/EP1347750A1/fr
Publication of WO2002047670A1 publication Critical patent/WO2002047670A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/344—Disorders of the penis and the scrotum and erectile dysfuncrion

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

L'invention porte sur l'utilisation d'un inhibiteur d'un neuropeptide Y (NPY), de préférence d'un récepteur de NPY Y1, cet inhibiteur étant sélectif pour un récepteur de NPY ou NPY Y1 associé aux organes génitaux mâles, dans la préparation/fabrication d'un médicament destiné à être utilisé dans le traitement ou la prévention de la dysérection.
PCT/IB2001/002399 2000-12-15 2001-12-10 Traitement du dysfonctionnement sexuel male WO2002047670A1 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
EP01270206A EP1347750A1 (fr) 2000-12-15 2001-12-10 Traitement du dysfonctionnement sexuel male
KR10-2003-7007946A KR20030061441A (ko) 2000-12-15 2001-12-10 남성 성기능 장애의 치료
NZ526925A NZ526925A (en) 2000-12-15 2001-12-10 Treatment of male sexual dysfunction
IL15577501A IL155775A0 (en) 2000-12-15 2001-12-10 Treatment of male sexual dysfunction
HU0400528A HUP0400528A2 (hu) 2000-12-15 2001-12-10 Neuropeptidáz Y inhibitor alkalmazása férfiak szexuális funkciózavarának kezelésére alkalmas gyógyszerkészítmény előállítására
CA002431747A CA2431747A1 (fr) 2000-12-15 2001-12-10 Traitement du dysfonctionnement sexuel male
AU2002220977A AU2002220977A1 (en) 2000-12-15 2001-12-10 Treatment of male sexual dysfunction
JP2002549244A JP2004522720A (ja) 2000-12-15 2001-12-10 雄性性的機能障害の処置

Applications Claiming Priority (14)

Application Number Priority Date Filing Date Title
GB0030647.2 2000-12-15
GB0030647A GB0030647D0 (en) 2000-12-15 2000-12-15 Treatment of male sexual dysfunction
GB0108730A GB0108730D0 (en) 2001-04-06 2001-04-06 Treatment of male sexual dysfunction
GB0108730.3 2001-04-06
GB0109910.0 2001-04-23
GB0109910A GB0109910D0 (en) 2001-04-23 2001-04-23 Treatment of sexual dysfunction
GB0111037A GB0111037D0 (en) 2001-05-04 2001-05-04 Treatment of sexual dysfunction
GB0111037.8 2001-05-04
US09/895,367 2001-06-29
US09/895,367 US20020028799A1 (en) 2000-07-06 2001-06-29 Treatment of male sexual dysfunction
US09/905,846 US6878529B2 (en) 2000-07-14 2001-07-13 Compounds for the treatment of sexual dysfunction
US09/905,846 2001-07-13
GB0120679.6 2001-08-24
GB0120679A GB0120679D0 (en) 2001-08-24 2001-08-24 Treatment of male sexual dysfunction

Publications (1)

Publication Number Publication Date
WO2002047670A1 true WO2002047670A1 (fr) 2002-06-20

Family

ID=27562581

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2001/002399 WO2002047670A1 (fr) 2000-12-15 2001-12-10 Traitement du dysfonctionnement sexuel male

Country Status (9)

Country Link
EP (1) EP1347750A1 (fr)
JP (1) JP2004522720A (fr)
CN (1) CN1496254A (fr)
AU (1) AU2002220977A1 (fr)
CA (1) CA2431747A1 (fr)
HU (1) HUP0400528A2 (fr)
IL (1) IL155775A0 (fr)
NZ (1) NZ526925A (fr)
WO (1) WO2002047670A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6855532B2 (en) 1999-11-19 2005-02-15 Solvay Pharmaceuticals B.V. Human enzymes of the metalloprotease family
EP1635813A2 (fr) * 2003-06-06 2006-03-22 Merck &amp; Co. Inc. Polytherapie permettant de traiter la dyslipidemie
US7189755B2 (en) 2001-08-10 2007-03-13 Palatin Technologies, Inc. Pyrrolidine melanocortin-specific compounds
US8101371B2 (en) 2007-10-18 2012-01-24 Musc Foundation For Research Development Methods for the diagnosis of genitourinary cancer
CN111840508A (zh) * 2020-07-17 2020-10-30 北京清大赛尔生物科技有限公司 一种预防及治疗男性性功能障碍的外用制剂及其应用

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1925307A1 (fr) * 2006-11-03 2008-05-28 Emotional Brain B.V. Utilisation de 3-alpha-androstanediol pour le traitement des dysfonctions sexuelles
DE102009018668A1 (de) 2009-04-23 2010-11-25 Igor Lier Faltbare Duschkabine
SG10201509316SA (en) * 2010-11-15 2015-12-30 Neuroderm Ltd Continuous Administration Of L-Dopa, Dopa Decarboxylase Inhibitors, Catechol-O-Methyl Transferase Inhibitors And Compositions For Same

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998052890A1 (fr) * 1997-05-21 1998-11-26 Eli Lilly And Company Antagonistes du recepteur des 3-arylpropylamino neuropeptides y
EP1097718A1 (fr) * 1999-11-08 2001-05-09 Pfizer Limited Antagonistes du neuropeptide Y (NPY) pour le traitement de la dysfonction sexuelle chez la femme
WO2001070708A1 (fr) * 2000-03-23 2001-09-27 Merck & Co., Inc. Piperidines substituees en tant qu'agonistes du recepteur de la melanocortine
WO2001085173A1 (fr) * 2000-05-10 2001-11-15 Bristol-Myers Squibb Company Derives d'alkylamine d'antagonistes de dihydropyridine npy
WO2001085098A2 (fr) * 2000-05-10 2001-11-15 Bristol-Myers Squibb Company Derives de dihydropyridine a squarate antagonistes de npy
WO2001085690A1 (fr) * 2000-05-10 2001-11-15 Bristol-Myers Squibb Company Derives 4-alkyle et 4-cycloalkyle d'antagonistes de npy de dihydropyridine

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998052890A1 (fr) * 1997-05-21 1998-11-26 Eli Lilly And Company Antagonistes du recepteur des 3-arylpropylamino neuropeptides y
EP1097718A1 (fr) * 1999-11-08 2001-05-09 Pfizer Limited Antagonistes du neuropeptide Y (NPY) pour le traitement de la dysfonction sexuelle chez la femme
WO2001070708A1 (fr) * 2000-03-23 2001-09-27 Merck & Co., Inc. Piperidines substituees en tant qu'agonistes du recepteur de la melanocortine
WO2001085173A1 (fr) * 2000-05-10 2001-11-15 Bristol-Myers Squibb Company Derives d'alkylamine d'antagonistes de dihydropyridine npy
WO2001085098A2 (fr) * 2000-05-10 2001-11-15 Bristol-Myers Squibb Company Derives de dihydropyridine a squarate antagonistes de npy
WO2001085690A1 (fr) * 2000-05-10 2001-11-15 Bristol-Myers Squibb Company Derives 4-alkyle et 4-cycloalkyle d'antagonistes de npy de dihydropyridine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NAYLOR, A.M.: "Endogenous neurotransmitters mediating penile erection", BRITISH JOURNAL OF UROLOGY, vol. 81, no. 3, 1998, pages 424 - 431, XP001062446 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6855532B2 (en) 1999-11-19 2005-02-15 Solvay Pharmaceuticals B.V. Human enzymes of the metalloprotease family
US7189755B2 (en) 2001-08-10 2007-03-13 Palatin Technologies, Inc. Pyrrolidine melanocortin-specific compounds
US7326707B2 (en) 2001-08-10 2008-02-05 Palatin Technologies Incorporated Bicyclic melanocortin-specific compounds
US7601753B2 (en) 2001-08-10 2009-10-13 Palatin Technologies, Inc. Pyrrolidine melanocortin-specific compounds
EP1635813A2 (fr) * 2003-06-06 2006-03-22 Merck &amp; Co. Inc. Polytherapie permettant de traiter la dyslipidemie
EP1635813A4 (fr) * 2003-06-06 2009-07-01 Merck & Co Inc Polytherapie permettant de traiter la dyslipidemie
US8101371B2 (en) 2007-10-18 2012-01-24 Musc Foundation For Research Development Methods for the diagnosis of genitourinary cancer
CN111840508A (zh) * 2020-07-17 2020-10-30 北京清大赛尔生物科技有限公司 一种预防及治疗男性性功能障碍的外用制剂及其应用

Also Published As

Publication number Publication date
IL155775A0 (en) 2003-12-23
JP2004522720A (ja) 2004-07-29
CA2431747A1 (fr) 2002-06-20
EP1347750A1 (fr) 2003-10-01
NZ526925A (en) 2005-03-24
HUP0400528A2 (hu) 2004-06-28
CN1496254A (zh) 2004-05-12
AU2002220977A1 (en) 2002-06-24

Similar Documents

Publication Publication Date Title
US20030119714A1 (en) Treatment of male sexual dysfunction
US20020028799A1 (en) Treatment of male sexual dysfunction
SK16722000A3 (sk) Zlúčeniny na liečenie sexuálnej dysfunkcie u žien
JP2008266338A (ja) 性機能障害を治療するための選択的ドーパミンｄ３受容体アゴニスト
AU2002220977A1 (en) Treatment of male sexual dysfunction
US20150072995A1 (en) Treatment of male sexual dysfunction
ZA200304460B (en) Treatment of male sexual dysfunction.
EP1313507A2 (fr) Composition pharmaceutique
US20040185094A1 (en) Pharmaceutical
KR20030061441A (ko) 남성 성기능 장애의 치료
JP2013151511A (ja) 雄性の性機能障害の治療
AU2003201471A1 (en) Treatment of male sexual dysfunction
ZA200300120B (en) Treatment of Male sexual dysfunction.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2001270206

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 155775

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2002220977

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2003/04460

Country of ref document: ZA

Ref document number: 200304460

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2431747

Country of ref document: CA

Ref document number: 1020037007946

Country of ref document: KR

Ref document number: 018205569

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2002549244

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 526925

Country of ref document: NZ

WWP Wipo information: published in national office

Ref document number: 1020037007946

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2001270206

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 1-2003-500509

Country of ref document: PH

WWP Wipo information: published in national office

Ref document number: 526925

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 526925

Country of ref document: NZ

WWR Wipo information: refused in national office

Ref document number: 1020037007946

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 2001270206

Country of ref document: EP